Spots Global Cancer Trial Database for hdac
Every month we try and update this database with for hdac cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or SĂ©zary Syndrome (SS) | NCT02953301 | Mycosis Fungoid... Sezary Syndrome Lymphoma, T-Cel... | resminostat Placebo | 18 Years - | 4SC AG | |
| Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | NCT00798720 | Carcinoma, Non ... | vorinostat bortezomib | 18 Years - | University of Wisconsin, Madison | |
| 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma | NCT01277406 | Advanced Colore... | 4SC-201(Resmino... FOLFIRI | 18 Years - | 4SC AG | |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or SĂ©zary Syndrome (SS) | NCT02953301 | Mycosis Fungoid... Sezary Syndrome Lymphoma, T-Cel... | resminostat Placebo | 18 Years - | 4SC AG | |
| Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma | NCT01037478 | Hodgkin's Lymph... | Resminostat (4S... | 18 Years - | 4SC AG | |
| A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors | NCT02414516 | Solid Tumor | OBP-801 | 18 Years - | Oncolys BioPharma Inc | |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors | NCT00728793 | Tumors | CUDC-101 | 18 Years - | Curis, Inc. | |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | NCT01463046 | Acute Myeloid L... Advanced Myelod... | Panobinostat Cytarabine Daunorubicin | 18 Years - | University of California, San Francisco | |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | NCT02018926 | Myelodysplastic... | Mocetinostat Azacitidine | 18 Years - | Mirati Therapeutics Inc. | |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | NCT02018926 | Myelodysplastic... | Mocetinostat Azacitidine | 18 Years - | Mirati Therapeutics Inc. | |
| Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients | NCT01702285 | Cancer | CUDC-101 | 18 Years - | Curis, Inc. | |
| A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors | NCT02414516 | Solid Tumor | OBP-801 | 18 Years - | Oncolys BioPharma Inc | |
| Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | NCT02204553 | Multiple Myelom... | Panobinostat | 18 Years - | Novartis | |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or SĂ©zary Syndrome (SS) | NCT02953301 | Mycosis Fungoid... Sezary Syndrome Lymphoma, T-Cel... | resminostat Placebo | 18 Years - | 4SC AG | |
| 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma | NCT01277406 | Advanced Colore... | 4SC-201(Resmino... FOLFIRI | 18 Years - | 4SC AG | |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | NCT01463046 | Acute Myeloid L... Advanced Myelod... | Panobinostat Cytarabine Daunorubicin | 18 Years - | University of California, San Francisco | |
| A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors | NCT00503451 | Non-Hodgkin Lym... Neoplasms | LBH589 | 18 Years - | Novartis | |
| 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma | NCT00943449 | Hepatocellular ... | 4SC-201 Sorafenib | 18 Years - | 4SC AG | |
| 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma | NCT00943449 | Hepatocellular ... | 4SC-201 Sorafenib | 18 Years - | 4SC AG | |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors | NCT00728793 | Tumors | CUDC-101 | 18 Years - | Curis, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
